Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology insulin pump management task force

Insulin pumps have come of age. With their proliferation in medical practice, some guidance is necessary for prospective and current prescribers to ensure their optimal and safe use. This document summarizes the current state-of- the-art of continuous subcutaneous insulin infusion (CSII) options available to patients who are using basal-bolus insulin management to control their diabetes mellitus. The American Association of Clinical Endocrinologists (AACE) published its first Consensus Statement on Insulin Pump Management in 2010. This document provides an update to that statement and attempts to avoid the repetition of some general but still valid information. The current version includes extensive updates regarding the State of Insulin Pump Technology (Section 1). This section includes a discussion of improvements to the functional features of pumps and insulin action acceleration technology. Additionally, new devices are discussed, including the first pump with a low-glucose "threshold suspend" system (MiniMed 530G with Enlite; Medtronic, Minneapolis, MN) and a new disposable insulin delivery system for type 2 diabetes